術後2か月で肝転移を来した早期乳癌の1例
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
乳癌患者の約20%が再発を経験し,再発治療後,50~70%が最終的に肝転移を来す.肝転移の予後は悪く治癒は期待できない.そのため,生命の延長,生活の質の維持を目標とした治療が選択されなければならない.術後内分泌補助療法中,術後2か月で肝転移を来たすという非常に稀な早期乳癌症例に対し,化学療法か内分泌療法かの治療選択に難渋したが,多くの臨床試験の結果,ゲノム検査なども参考にアベマシクリブとフルベストラントの併用療法を選択した.治療開始後5か目の効果判定でpartial response(PR)と判定され,以後7か月にわたりPRを維持している.Approximately 20% of breast cancer patients experience recurrence, and after treatment for recurrence, 50-70% eventually develop liver metastases. The prognosis for liver metastases is poor, and a cure is generally not expected. Therefore, treatment should aim to prolong life and maintain quality of life. In a very rare case of early-stage breast cancer that developed liver metastases within two months during postoperative adjuvant endocrine therapy, the choice between chemotherapy and endocrine therapy was challenging. However, based on the results of numerous clinical trials and genomic testing, a combination therapy of abemaciclib and fulvestrant was selected. A partial response was confirmed on the fifth month following initiation of treatment, and this response has been sustained for seven months thereafter.
Fields of Study & Subjects
Advanced Breast Cancer Therapies
Breast Cancer Treatment Studies
Breast Lesions and Carcinomas
Publication details
- Journal / source
- Institutional Repositories DataBase (IRDB)
- Volume
- 73
- Issue
- 1
- Pages
- 34–42
- Publication date
- 1 March 2026
- Language
- JA